Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Lonza May End Jazz Pharma Supply Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

Lonza May End Jazz Pharma Supply Pact

Lonza, Inc. has terminated its Sodium Gamma Hydroxybutyrate development and supply agreement with Jazz Pharmaceuticals, Inc.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Lonza, Inc. has terminated its Sodium Gamma Hydroxybutyrate development and supply agreement with Jazz Pharmaceuticals, Inc. The original agreement dates back to November 6, 1996 and, as amended, will end December 31, 2011.

Under the agreement, Jazz Pharma purchases its worldwide supply of sodium oxybate, the API in Xyrem (sodium oxybate) oral solution, from Lonza. Jazz Pharma may terminate the agreement with 30 days’ notice if Lonza is unable to meet the company’s minimum requirements or timeframes for supply.

Lonza recently announced plans to close its U.S. facility where it manufactures sodium oxybate. The two companies have been working together to ensure a continued supply. Lonza remains contractually obligated to supply the API through December 2011; however, Jazz Pharma has also identified potential new manufacturers to meet its requirements.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters